SCHEMBL27415464

SCHEMBL27415464

Cn1nc(OC2CC2)cc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
GRN P28799 1/20 0.46
SORT1 Q99523 1/20 0.46
PKM P14618 2/20 0.35
ACSL1 P33121 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
CCNE1 P24864 2/20 0.34
CDK2 P24941 2/20 0.34
GSK3B P49841 1/20 0.34
CACNB4 O00305 2/20 0.34
CACNA1A O00555 2/20 0.34
CACNA1G O43497 2/20 0.34
CACNG3 O60359 2/20 0.34
CACNA1F O60840 2/20 0.34
CACNA1H O95180 2/20 0.34
CACNB3 P54284 2/20 0.34
CACNA2D1 P54289 2/20 0.34
CACNG7 P62955 2/20 0.34
CACNA1B Q00975 2/20 0.34
CACNA1D Q01668 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4552480 0.86 KDM4E (0.44) KDM4EGRNSORT1CCNE1CDK2
SCHEMBL21604151 0.84 CCNE1 (0.39) KDM4EACSL1CCNE1CDK2GSK3B
SCHEMBL1853083 0.82 GPR119 (0.52) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL4282720 0.79 GPR119 (0.45) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL2516746 0.78 KDM4E (0.53) KDM4EGRNSORT1PKMCCNE1
SCHEMBL21597708 0.77 KDM4E (0.43) KDM4EGRNSORT1PKMNR1H4
SCHEMBL2522003 0.77 KDM4E (0.49) KDM4EGRNSORT1PKMNR1H4
SCHEMBL27415465 0.74 CACNB4 (0.36) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL26105967 0.74 KDM4E (0.43) KDM4EGRNSORT1NR1H4CCNE1
SCHEMBL27028206 0.73 KDM4E (0.42) KDM4EGRNSORT1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 KDM4E 3965/4885GRN 1369/4885SORT1 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.